- Tags: cornea
Business
Voiant acquires AI-based ophthalmic image analysis startup Voxeleron
Software and clinical trial expertise to combine into an AI-based integrated platform for retinal and corneal imaging, with a goal of expedited patient treatment delivery.
Pipeline
OKYO's urcosimod demonstrates long-term stability for NCP
With a real-world study ongoing, urcosimod’s +2.5-year shelf stability further supports a potential NDA submission for regulatory approval down the road.
Business
Pantheon Vision and Eyedeal Medical to develop bioengineered corneal implant
Collaboration involves advancement and commercialization of Pantheon’s artificial cornea as the company nears a potential premarket approval submission.
Business
Alcon purchases majority stake in Aurion Biotech
Company replaces CEO and founder Greg Kunst, gaining access to groundbreaking CED cell therapy with plans for phase 3 clinical trials expected later this year.
Research
Rare tooth-in-eye surgery restores vision in the blind
First patients in Canada undergo osteo-odonto keratoprosthesis to regain eyesight after severe corneal blindness.
Pipeline
OKYO Pharma seeks Fast Track designation for NCP candidate
Designation would give urcosimod (formerly OK-101) an expedited pathway to potentially become the first approved treatment for this orphan disease.
Pipeline
FDA accepts NDA submission for Glaukos's Epioxa
Epi-on CXL iLink therapy could become the first noninvasive procedure with no need for corneal epithelium removal to treat keratoconus eyes.
Events
First-ever Corneal Health Summit kicks off in April
A virtual one-day event for optometrists to feature industry-leading clinical experts, COPE-accredited sessions, and free CE credits.
Business
TECLens raises $9.3M in funding for non-invasive refractive tech
The company's corneal CXL-based, non-incisional refractive correction procedure is designed to reshape the corneal for presbyopes and myopes.
Pipeline
Pantheon Vision reports positive pre-clinical FDA meeting on bioengineered corneal implants
This marks the third-presubmission meeting as the company advances clinical development of a potential alternative to corneal transplants.
Business
VisiRose raises $3M to advance RB-PDAT therapeutic toward regulatory approval
Funding will support ongoing clinical development of photodynamic therapy candidate for infectious keratitis and future IND submission to FDA.
Products
FDA approves Zeiss MEL 90 excimer laser
Integrated with the company’s Corneal Refractive Workflow, this laser system is indicated to reduce or eliminate myopia, hyperopia, and mixed astigmatism.
Products
FDA clears Epithelial Thickness Module for Heidelberg's imaging platform
Exclusive to the ANTERION segment imaging platform, this module is designed to improve precision and outcomes in cornea, cataract, and refractive care.
Pipeline
Aurion Biotech releases topline phase 1/2 data on allogeneic cell therapy for CED
Findings support potential for high-dose AURN001 as a one-time intracameral injection that regenerates healthy cells from a single donor cornea.Pipeline
Glaukos submits Epioxa NDA for keratoconus
Next-gen corneal cross linking therapy could become the first to not require removal of the corneal epithelium.
Pipeline
New findings support Brightstar Therapeutics' corneal allograft for LSCD
Pilot study investigates use of BrightMEM as an alternative form of corneal transplantation involving Descemet’s membrane.Pipeline
Glaukos reports phase 3 topline data on Epioxa for keratoconus
Findings will support an anticipated NDA submission for the second-generation iLink therapy by the end of 2024.
Research
Long-term corneal endothelial changes noted after COVID
Corneal endothelial cell density and hexagonality negatively impacted ~5 months after COVID-19 infection.
Research
Study identifies key variables for keratoconus progression risk
New parameter may be the most significant indicator for corneal thinning and Max-K progression.
Research